Bacteriophage strains and their applications
Inventors
Wojtasik, Arkadiusz • Gorecka, Elzbieta • Wojcik, Ewelina • STANCZYK, Malgorzata • KOLSUT, Joanna • KLIMCZAK, Justyna • Dastych, Jaroslaw • SIWICKI, Andrzej • SCHULZ, Patrycja
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11077155-B2
Publication Date
2021-08-03
Expiration Date
Abstract
New strains of bacteriophages and their applications are revealed, useful especially in fish farming.
Core Innovation
The invention relates to a method of preventing or treating an infection in a farmed fish by treating the farmed fish by immersion in a composition comprising at least 10^5 PFU/ml of bacteriophage. The bacteriophage is selected from specified deposited strains deposited in the Polish Collection of Microorganisms under the indicated accession numbers, including strain 25AhydR2PP (F/00096), strain 50AhydR13PP (F/00094), strain 22PfluR64PP (F/00098), strain 67PfluR64PP (F/00099), strain 71PfluR64PP (F/00100), strain 98PfluR60PP (F/00095), and strain 60AhydR15PP (F/00101).
The document addresses prevention and treatment of fish infections in aquaculture, where the infections are caused by Aeromonas, including Aeromonas hydrophila and Aeromonas salmonicida, and Pseudomonas, including Pseudomonas fluorescens. It positions phage therapy as an approach for aquaculture infections and describes rationale relative to antibiotics, including the stated advantages of using bacteriophages for preventing or treating the infections.
The document further describes phage preparations and phage cocktails, reporting that the phage cocktails outperform single phages in vitro. The deposited bacteriophage strains are characterized using restriction profiles and genomic homology classification, including groups such as Myoviridae (T4-like, T7-like) and Podoviridae, and in vivo efficacy in carp against P. fluorescens is described as reduced mortality after immersion treatment.
Claims Coverage
The document provides coverage through one independent claim defining a farmed-fish immersion method using a bacteriophage composition with at least 10^5 PFU/ml, specifying seven deposited bacteriophage strains. Dependent claims refine the independent claim by adding treatment timing and repetition and narrowing the target infection to Aeromonas and Pseudomonas, including Aeromonas hydrophila, Aeromonas salmonicida, and Pseudomonas fluorescens.
Immersion treatment composition with at least 10^5 PFU/ml bacteriophage selected from specified deposited strains
A method of preventing or treating an infection in a farmed fish by treating the farmed fish by immersion in a composition comprising at least 10^5 PFU/ml of bacteriophage, wherein the bacteriophage is selected from strains 25AhydR2PP (F/00096), 50AhydR13PP (F/00094), 22PfluR64PP (F/00098), 67PfluR64PP (F/00099), 71PfluR64PP (F/00100), 98PfluR60PP (F/00095), and 60AhydR15PP (F/00101).
Treatment duration of one hour
The method wherein the immersion treatment lasts for a period comprising one hour.
Repeated immersion at 24-hour intervals
The method wherein the immersion treatment is repeated at 24-hour time intervals.
Targeting infection caused by Aeromonas or Pseudomonas
The method wherein the infection is caused by Aeromonas sp. or Pseudomonas sp.
Targeting infection caused by specific bacterial species
The method where the infection is caused by Aeromonas hydrophila, Aeromonas salmonicida, or Pseudomonas fluorescens.
Claim coverage centers on immersion-based prevention or treatment of farmed-fish infections using a bacteriophage composition at at least 10^5 PFU/ml, restricted to the specifically identified deposited strains. Dependent claims further define treatment timing and repetition and narrow the bacterial causes of infection to Aeromonas or Pseudomonas, and ultimately to Aeromonas hydrophila, Aeromonas salmonicida, or Pseudomonas fluorescens.
Stated Advantages
Phage therapy is presented as having key advantages over antibiotics.
Phage cocktails outperform single phages in vitro.
Safety is described as maintained, with hematological and biochemical markers unchanged.
Enhanced innate cellular and humoral immunity parameters are reported.
In vivo efficacy is described as reduced mortality in carp after immersion treatment against P. fluorescens, with improved outcomes after double administration.
Documented Applications
Preventing or treating aquaculture infections in farmed fish by immersion in a bacteriophage composition.
Preventing or treating infections in carp caused by Pseudomonas fluorescens, with reduced mortality after immersion treatment.
Preventing or treating fish infections caused by Aeromonas, including Aeromonas hydrophila and Aeromonas salmonicida, and Pseudomonas, including Pseudomonas fluorescens.
Interested in licensing this patent?